Punganuru Surendra R, Mostofa A G M, Madala Hanumantha Rao, Basak Debasish, Srivenugopal Kalkunte S
Department of Biomedical Sciences and Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, 1406 S. Coulter Dr., Amarillo, TX 79106, USA.
Department of Biomedical Sciences and Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, 1406 S. Coulter Dr., Amarillo, TX 79106, USA.
Bioorg Med Chem Lett. 2016 Jun 15;26(12):2829-2833. doi: 10.1016/j.bmcl.2016.04.062. Epub 2016 Apr 22.
Ethacrynic acid (EA), a known inhibitor of the neoplastic marker glutathione S-transferase P1 and other GSTs, exerts a weak antiproliferative activity against human cancer cells. The clinical use of EA (Edecrin) as an anticancer drug is limited by its potent loop diuretic activity. In this study, we developed a non-diuretic 2-amino-2-deoxy-d-glucose conjugated EA (EAG) to target tumors cells via the highly expressed glucose transporter 1 (GLUT1). Cell survival assays revealed that EAG had little effect on normal cells, but was cytotoxic 3 to 4.5-fold greater than EA. Mechanistically, the EAG induced selective cell death in cancer cells by inhibiting GSTP1 and generating abundant reactive oxygen species. Furthermore, EAG induced p21(cip1) expression and a G2/M cell cycle block irrespective of the p53 gene status in tumor cells. These data encourage the development of new EA analogs.
依他尼酸(EA)是一种已知的肿瘤标志物谷胱甘肽S-转移酶P1及其他谷胱甘肽S-转移酶的抑制剂,对人类癌细胞具有微弱的抗增殖活性。EA(利尿酸)作为抗癌药物的临床应用因其强大的髓袢利尿活性而受到限制。在本研究中,我们开发了一种非利尿性的2-氨基-2-脱氧-D-葡萄糖缀合依他尼酸(EAG),通过高表达的葡萄糖转运蛋白1(GLUT1)靶向肿瘤细胞。细胞存活分析显示,EAG对正常细胞影响很小,但细胞毒性比EA大3至4.5倍。从机制上讲,EAG通过抑制GSTP1并产生大量活性氧诱导癌细胞选择性死亡。此外,无论肿瘤细胞中的p53基因状态如何,EAG均可诱导p21(cip1)表达并导致G2/M期细胞周期阻滞。这些数据为新型EA类似物的开发提供了依据。